Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2013; 19(10): 1602-1610
Published online Mar 14, 2013. doi: 10.3748/wjg.v19.i10.1602
Figure 1
Figure 1 Schematic representation of analyses carried out on recruited human immunodeficiency virus infected individuals at Jos University Teaching Hospital, Nigeria. HIV: Human immunodeficiency virus; ART: Antiretroviral therapies; APIN: Acquired immunodeficiency syndrome prevention initiative in Nigeria.
Figure 2
Figure 2 Rates of hepatitis co-infection of human immunodeficiency virus infected individuals in both genders (A) and men (B) among acquired immunodeficiency syndrome prevention initiative in Nigeria cohort, Jos University Teaching Hospital; 2004-2010. HBV: Hepatitis B virus; HCV: Hepatitis C virus.
Figure 3
Figure 3 Prevalence of hepatitis B, hepatitis C, hepatitis B and C and liver disease diagnoses among human immunodeficiency virus infected individuals at Jos University Teaching Hospital, 2004-2010.
Figure 4
Figure 4 Baseline HIV viral load by hepatitis status among HIV infected patients at AIDS Prevention Initiative in Nigeria, Jos University Teaching Hospital, 2004-2010. HBV: Hepatitis B virus; HCV: hepatitis C virus.
Figure 5
Figure 5 Median CD4 increase by hepatitis status following antiretroviral therapies at Jos University Teaching Hospital, 2004-2010. HBV: Hepatitis B virus; HCV: hepatitis C virus.